IP Library Granted Patent US 11,077,067
Granted Patent B2
US 11,077,067 · App. 17/008,108 · Granted Aug 3, 2021

Minimizing agglomeration, aeration, and preserving the coating of pharmaceutical compositions comprising ibuprofen

Inventors: Rosaleen McLaughlin (Swindon, GB); Simon Andrew Martyn Howes (Swindon, GB); Craig Wheadon (Swindon, GB); Jonathon Whitehouse (Herne Bay, GB); Adam Parker (Swindon, GB)
Assignee: Catalent U.K. Swindon Zydis Limited
A61K9/5073A61K9/501A61K9/5015A61K9/5089A61K31/192A61K47/26A61K47/36A61K47/42
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,077,067
App. No.
17/008,108
Granted
Aug 3, 2021
Kind
B2
Abstract

Provided are pharmaceutical compositions and methods for preparing pharmaceutical compositions comprising Ibuprofen using solventless mixing methods. Excess coating material that is not bound to coated Ibuprofen may be removed by a sieving process. Coating and dosing ratios can also be optimized to minimize the amount of excess unbound coating material. Additionally, the compositions can be formulated to preserve the functional coating of coated Ibuprofen and to minimize aeration of Ibuprofen when mixed into suspension.

Claims (42)

1. A pharmaceutical composition comprising:

more than 75% w/w coated API, wherein the API coating comprises a first coating material and 0.5-5% w/w silica surrounding, partially embedded in, and/or embedded in the first coating material;

3-7% w/w matrix former;

2-6% w/w structure former;

0.1-2% w/w anti-aerating agent; and

0.01-0.2% w/w viscosity modifier.

2. The pharmaceutical composition of claim 1 , wherein the first coating material comprises 10-30% w/w of the coated API.

3. The pharmaceutical composition of claim 1 , wherein the first coating material comprises a wax.

4. The pharmaceutical composition of claim 3 , wherein the first coating material comprises one or more of carnauba wax, synthetic wax, or candelilla wax.

5. The pharmaceutical composition of claim 1 , wherein the matrix former comprises one or more of a water soluble material, a water dispersible material, a polypeptide, a polysaccharide, a polyvinyl alcohol, a polyvinylpyrrolidone, and an acacia.

6. The pharmaceutical composition of claim 5 , wherein the matrix former comprises a polypeptide.

7. The pharmaceutical composition of claim 6 , wherein the polypeptide comprises gelatin.

8. The pharmaceutical composition of claim 1 , wherein the structure former comprises one or more of mannitol, dextrose, lactose, galactose, and cyclodextrin.

9. The pharmaceutical composition of claim 8 , wherein the structure former comprises mannitol.

10. The pharmaceutical composition of claim 1 , wherein the viscosity modifier comprises xanthan gum.

11. The pharmaceutical composition of claim 1 , wherein the anti-aerating agent comprises one or more of a terpene or a terpinol.

12. The pharmaceutical composition of claim 11 , wherein the anti-aerating agent comprises limonene.

13. The pharmaceutical composition of claim 1 , wherein the anti-aerating agent comprises one or more of orange flavor, lemon flavor, grapefruit flavor, lime flavor, strawberry flavor, or peppermint flavor.

14. The pharmaceutical composition of claim 1 , further comprising a sweetener.

15. The pharmaceutical composition of claim 1 , wherein the API comprises Ibuprofen.

16. A method of preparing a pharmaceutical composition comprising:

forming a pharmaceutical suspension comprising:

30-50% w/w a coated API, wherein the API coating comprises a first coating material and 0.5-5% w/w silica surrounding, partially embedded in, and/or embedded in the first coating material;

50-70% w/w a matrix solution or suspension comprising:

1-5% w/w a matrix former;

0.5-4% w/w a structure former;

0.01-0.1% w/w a viscosity modifier;

0.1-1% w/w an anti-aerating agent; and

a solvent;

dosing the pharmaceutical suspension into a mold;

freezing the pharmaceutical suspension in the mold; and

freeze drying the dosed pharmaceutical suspension in the mold to form the pharmaceutical composition.

17. The method of claim 16 , wherein the first coating material comprises 10-30% w/w of the coated API.

18. The method of claim 16 , wherein the first coating material comprises one or more of carnauba wax, synthetic wax, or candelilla wax.

19. The method of claim 16 , wherein the matrix former comprises gelatin.

20. The method of claim 16 , wherein the structure former comprises mannitol.

21. The method of claim 16 , wherein the viscosity modifier comprises xanthan gum.

22. The method of claim 16 , wherein the anti-aerating agent comprises one or more of a terpene or a terpinol.

23. The method of claim 22 , wherein the anti-aerating agent comprises limonene.

24. The method of claim 16 , wherein the matrix solution or suspension comprises a sweetener.

25. The method of claim 16 , wherein the API comprises Ibuprofen.

26. The method of claim 16 , wherein the solvent comprises water.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 30, 2021
From: MCLAUGHLIN, ROSALEEN; HOWES, SIMON ANDREW MARTYN; WHEADON, CRAIG; WHITEHOUSE, JONATHON; PARKER, ADAM
To: CATALENT U.K. SWINDON ZYDIS LIMITED
Reel/Frame 056717/0680 →
Continuity (5)
Continuation 16798130 · Feb 21, 2020
Provisional Application 62809293 · Feb 22, 2019
Provisional Application 62809287 · Feb 22, 2019
Provisional Application 62809307 · Feb 22, 2019
Related Publication 20200390716A1 · Dec 17, 2020
Cited By (3)
US 12,201,726 US 12,208,160 US 12,350,372